Concord Biotech Peer Comparison

Concord Biotech Ltd. stands out in the Pharmaceuticals & Drugs sector, demonstrating strong profitability metrics and efficient operations despite a unique growth trajectory. While peers exhibit varying strengths, Concord's low debt levels and solid ROE position it favorably, making it a competitive player within its industry.

• • Concord Biotech Ltd. has the highest ROE (21.88%) among its peers, indicating strong profitability relative to equity.
• • The company has a very low debt-equity ratio (0.0041), which enhances its financial stability and reduces risk.
• • Concord's revenue growth over three years (154.5%) is remarkable, although it shows no YoY growth, suggesting volatility in its revenue performance.

• • Concord Biotech Ltd.: Highest ROE (21.88%) and lowest debt-equity ratio (0.0041) indicate strong profitability and low financial risk.
• • Dr. Reddy's Laboratories Ltd.: Strong growth trajectory with high EPS (68.07) and solid profitability metrics.
• • Mankind Pharma Ltd.: High revenue growth YoY (18.12%) and solid profitability (ROE 23.15%).